Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Enanta Pharmaceuticals Inc

Company price
7.62 USD -0.36 ( 4.51%)
Last update at 2026-11-20T21:00:00Z
VOLUME
456467
Market Cap
357.95M

Momentum Score

…

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.56
Low
8.06
High
52 Week Price Range
7.05
Low
17.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapeutics, primarily for antiviral, respiratory and liver diseases. Long-term growth drivers include progression of its clinical-stage candidates, a chemistry-driven discovery platform and potential partnerships; positive clinical readouts or licensing could materially de-risk programs and support value realization. Investors may find the company attractive for its targeted pipeline and platform-based discovery approach.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.98
Dividend Yield
-
Revenue TTM
65.26M
Revenue Per Share
2.41
Gross Profit TTM
65.26M
Debt / Equity
3.11
ROE
-70.12%
Net Debt
168.76M
ROCE
-32.68%
Diluted EPS TTM
-2.27

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -83.55M -117.79M -131.00M -122.19M -107.58M
Net income -81.89M -116.05M -133.82M -121.75M -79.00M
Selling general administrative 43.93M 57.85M 52.89M 45.48M 32.54M
Gross profit 60.74M 67.64M 79.20M 86.16M 97.07M
Reconciled depreciation 4.59M 2.34M 2.37M 2.97M 3.33M
Ebit -75.87M -106.85M -125.85M -123.84M -112.91M
Ebitda -70.78M -104.51M -123.48M -120.95M -109.57M
Depreciation and amortization 5.09M 2.34M 2.37M 2.89M 3.33M
Non operating income net other - - - 0.08M -0.03M
Operating income -85.35M -121.69M -137.21M -123.84M -109.57M
Other operating expenses 150.67M 189.33M 216.41M 210.00M 206.65M
Interest expense 7.68M 10.94M 5.15M 1.57M 5.33M
Tax provision -1.66M -1.74M 2.82M -0.43M -28.58M
Interest income 9.44M 14.77M 11.36M 1.57M 2.02M
Net interest income 1.76M 3.83M 6.21M 1.57M 2.02M
Income tax expense -1.66M -1.74M 2.82M -0.43M -28.58M
Total revenue 65.32M 67.64M 79.20M 86.16M 97.07M
Total operating expenses 146.09M 189.33M 216.41M 210.00M 206.65M
Cost of revenue 4.59M - - - -
Total other income expense net 1.80M 3.90M 6.21M 1.66M 1.99M
Net income from continuing ops -81.89M -116.05M -133.82M -121.75M -79.00M
Net income applicable to common shares - - - -121.75M -79.00M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 280.73M 376.65M 462.27M 375.41M 438.79M
Other current assets 8.59M 13.02M 13.26M 13.45M 51.44M
Total liab 216.01M 247.84M 245.54M 54.08M 39.36M
Total stockholder equity 64.72M 128.81M 216.74M 321.33M 399.43M
Other current liab 12.75M 13.55M 35.08M 20.94M 22.43M
Common stock 0.21M 0.21M 0.21M 0.21M 0.20M
Capital stock 0.21M 0.21M 0.21M 0.21M 0.20M
Retained earnings -404.93M -323.04M -207.00M -73.18M 48.58M
Other liab - - - 0.45M 0.56M
Other assets - - - 4.66M 0.70M
Cash 32.30M 37.23M 85.39M 43.99M 57.21M
Total current liabilities 48.55M 57.53M 62.79M 29.83M 36.17M
Current deferred revenue - - 18.34M - -
Net debt 168.76M 188.82M -58.88M -18.73M -51.88M
Short term debt 33.86M 35.99M 5.28M 2.89M 4.20M
Short long term debt total 201.06M 226.06M 26.51M 25.26M 5.33M
Other stockholder equity 469.77M 451.34M 423.27M 396.61M 349.53M
Property plant equipment - - - 29.75M 10.65M
Total current assets 204.34M 299.85M 422.79M 311.71M 319.02M
Long term investments - - 0.00M 29.29M 108.42M
Net tangible assets - - - 321.33M 399.43M
Short term investments 156.57M 210.95M 284.52M 205.24M 186.80M
Net receivables 6.88M 38.65M 39.62M 49.04M 60.83M
Inventory - - - - -37.26M
Accounts payable 1.95M 8.00M 4.10M 6.00M 9.54M
Accumulated other comprehensive income -0.34M 0.30M -1.17M -3.72M -0.38M
Common stock total equity - - - 0.21M 0.20M
Retained earnings total equity - - - -73.18M 48.58M
Non currrent assets other 0.09M 0.09M 4.77M 4.66M 0.70M
Non current assets total 76.40M 76.80M 39.48M 63.70M 119.77M
Capital lease obligations 57.90M 55.47M 26.51M 25.26M 5.33M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments 40.35M 58.23M -53.58M 57.02M 37.74M
Change to liabilities - - - -4.63M 3.77M
Total cashflows from investing activities 40.35M 58.23M - 54.90M 36.99M
Net borrowings - -27.48M - - -
Total cash from financing activities -26.62M -27.63M 198.13M 20.03M 3.08M
Change to operating activities - - - -0.37M 6.84M
Net income -81.89M -116.05M -133.82M -121.75M -79.00M
Change in cash -5.54M -48.16M 41.39M -9.85M -29.93M
Begin period cash flow 41.20M 89.36M 47.96M 57.81M 87.74M
End period cash flow 35.66M 41.20M 89.36M 47.96M 57.81M
Total cash from operating activities -19.27M -78.76M -103.15M -84.78M -70.00M
Depreciation 5.09M 2.34M 2.37M 2.97M 3.33M
Change to account receivables 31.76M 0.97M 11.70M 3.26M -0.08M
Sale purchase of stock - - - 21.26M 3.61M
Other cashflows from financing activities -0.28M -0.29M 198.13M -1.23M 3.08M
Change to netincome - - - 27.21M 19.35M
Capital expenditures 12.90M 17.95M 9.06M 2.12M 0.75M
Change receivables - - - 3.26M -0.08M
Cash flows other operating - - - 9.66M -25.21M
Cash and cash equivalents changes - - - -9.85M -29.93M
Change in working capital 39.91M 7.13M 8.02M 6.79M -13.69M
Stock based compensation 18.57M 26.80M 28.22M 26.97M 20.99M
Other non cash items -0.95M 1.02M 2.60M 0.24M -1.98M
Free cash flow -32.17M -96.71M -112.21M -86.91M -70.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ENTA
Enanta Pharmaceuticals Inc
-0.36
4.51%
7.62 - 44.05 5.49 3.78 3.80 41.13
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

4 Kingsbury Avenue, Watertown, MA, United States, 02472

617 607 0800

120

Name Title Year Born
Dr. Jay R. Luly Pres, CEO & Director 1956
Mr. Paul J. Mellett Jr. Sr. VP of Fin. & Admin. and CFO 1955
Dr. Yat Sun Or Ph.D. Sr. VP of R&D and Chief Scientific Officer 1952
Ms. Tara Lynn Kieffer Ph.D. Sr. VP of New Product Strategy & Devel. 1978
Mr. Brendan Luu Sr. VP of Bus. Devel. NA
Ms. Jennifer Viera Sr. Director of Investor Relations & Corp. Communications NA
Mr. Nathaniel S. Gardiner J.D. Sr. VP, Gen. Counsel & Sec. 1954
Dr. Nathalie Adda M.D. Consultant 1966
Dr. Scott T. Rottinghaus Sr. VP & Chief Medical Officer NA
Dr. Jay R. Luly Ph.D. President, CEO & Director 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…